<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968383</url>
  </required_header>
  <id_info>
    <org_study_id>2.50/V/09</org_study_id>
    <nct_id>NCT00968383</nct_id>
  </id_info>
  <brief_title>Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment</brief_title>
  <acronym>COAT</acronym>
  <official_title>Late Percutaneous Coronary Intervention of the Occluded Infarct-Related Artery in Patients With Preserved Infarct Zone Viability Determined With Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cardiology, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Cardiology, Warsaw, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether opening an occluded infarcted artery 3-28
      days after an acute myocardial infarction in high-risk asymptomatic patients with preserved
      infarct zone viability improves left ventricular systolic function and volumes at 6 months
      follow-up. The secondary purpose is to assess the changes in myocardial tissue
      characteristics after late percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rapid restoration of blood flow in the infarct-related artery (IRA), one of the cornerstones
      of contemporary treatment of acute myocardial infarction (MI) prevents myocardial necrosis
      and its consequences. However, due to late presentation or failed fibrinolytic therapy up to
      one third of patients have persistently occluded IRA after MI.

      Recently, the Occluded Artery Trial (OAT) has demonstrated that percutaneous coronary
      intervention (PCI) with optimal medical therapy does not reduce the frequency of major
      adverse events compared to optimal medical therapy alone when performed on days 3-28 post MI
      in stable patients. Assessment of infarct zone viability was not used as an
      inclusion/exclusion criterion in the main OAT trial.

      Several studies confirm that patients with left ventricular systolic dysfunction and
      preserved myocardial viability (necrosis transmurality&lt;50% in most segments of the infarct
      zone) assessed with magnetic resonance imaging benefit from revascularization.

      Late opening of the occluded infarct-related artery only in patients with preserved
      myocardial tissue viability may lead to improvement of left ventricular volumes and function.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was prematurely terminated due to low enrollment.
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in systolic wall thickening (SWT)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in wall motion score index (WMSI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular end-diastolic volume (LVEDV)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular end-systolic volume (LVESV)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial tissue characteristics</measure>
    <time_frame>3-5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Optimal medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCI with optimal medical therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification plus percutaneous coronary intervention and coronary stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta adrenergic blockers</intervention_name>
    <description>Participants will receive beta adrenergic blockers.</description>
    <arm_group_label>Optimal medical therapy</arm_group_label>
    <arm_group_label>PCI with optimal medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platelet inhibitors</intervention_name>
    <description>Participants will receive platelet inhibitors.</description>
    <arm_group_label>Optimal medical therapy</arm_group_label>
    <arm_group_label>PCI with optimal medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statins</intervention_name>
    <description>Participants will receive statins.</description>
    <arm_group_label>Optimal medical therapy</arm_group_label>
    <arm_group_label>PCI with optimal medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitors and/or ARB and/or AA</intervention_name>
    <description>Participants will receive ACE inhibitors and/or ARB and/or AA</description>
    <arm_group_label>Optimal medical therapy</arm_group_label>
    <arm_group_label>PCI with optimal medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI with stenting</intervention_name>
    <description>Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.</description>
    <arm_group_label>PCI with optimal medical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrollment 3-28 days after an acute myocardial infarction.

          -  Infarct related artery occlusion (TIMI 0 or 1).

          -  High risk: left ventricular ejection fraction (LVEF)&lt;50% or LVEF&gt;50% and proximal
             coronary occlusion.

          -  Preserved infarct zone viability (necrosis transmurality &lt;50% in at least 4 segments
             out of 17 according to AHA classification).

        Exclusion Criteria:

          -  Unstable clinical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukasz A Malek, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cardiology, Warsaw, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariusz Kruk, M.D. PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Cardiology, Warsaw, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariusz Klopotowski, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Cardiology, Warsaw, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Hochman JS, Lamas GA, Knatterud GL, Buller CE, Dzavik V, Mark DB, Reynolds HR, White HD; Occluded Artery Trial Research Group. Design and methodology of the Occluded Artery Trial (OAT). Am Heart J. 2005 Oct;150(4):627-42.</citation>
    <PMID>16209957</PMID>
  </reference>
  <reference>
    <citation>Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006 Dec 7;355(23):2395-407. Epub 2006 Nov 14.</citation>
    <PMID>17105759</PMID>
  </reference>
  <reference>
    <citation>Malek LA, Reynolds HR, Forman SA, Vozzi C, Mancini GB, French JK, Dziarmaga M, Renkin JP, Kochman J, Lamas GA, Hochman JS. Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT). Am Heart J. 2009 Apr;157(4):724-32. doi: 10.1016/j.ahj.2008.12.008.</citation>
    <PMID>19332202</PMID>
  </reference>
  <reference>
    <citation>Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000 Nov 16;343(20):1445-53.</citation>
    <PMID>11078769</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>August 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Infarct Related Artery</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Medical treatment</keyword>
  <keyword>Tissue Viability</keyword>
  <keyword>Magnetic Resonance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
    <mesh_term>Adrenergic Antagonists</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

